Please login to the form below

Not currently logged in

EU patent extension for Pfizer's Lipitor

The European patent for Pfizer's blockbuster cholesterol drug, Lipitor, could be extended by six months due to new paediatric data concerning the treatment

The European patent for Pfizer's blockbuster cholesterol drug, Lipitor (atorvastatin), could be extended by six months due to new paediatric data concerning the treatment.

According to the Financial Times, the extended exclusivity to May 2012 for what is currently the company's largest selling therapy could earn Pfizer $800m.

Pfizer has said it plans to launch a chewable grape-flavoured version of Lipitor for children in the EU by November 2011.

The launch would coincide with the expiration of Lipitor's patent, when the opening of the market to generic competition would be expected to have a dramatic effect on the drug's current £11bn annual revenue.

However, Pfizer has requested a supplementary protection certificate across the EU, which would extend the company's control over supplies and pricing of Lipitor a further six months.

The certificate is part of EU regulations designed to encourage paediatric research regarding medicines.

Lipitor is usually prescribed to adults with high levels of cholesterol, however it can be given to children with the condition familial hypercholesterolaemia - a specific type of inherited high cholesterol that runs in the family.

11th July 2011


COVID-19 Updates and Daily News

Featured jobs


Add my company
Collected Group

Collected Group is a forward thinking healthcare communication company that supports biopharma and diagnostic companies to engage in more lasting...

Latest intelligence

When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...